Novo Nordisk's new obesity data tip the scales in semaglutide's favor as landmark pivotal program looms
Novo Nordisk has rolled out new data points to back its belief that their newly approved GLP-1 diabetes drug semaglutide also has the inside track on a blockbuster designation for obesity.
Novo’s researchers took center stage at the Endocrine Society’s annual conference in Chicago with a new round of Phase II numbers showing that the drug spurred weight loss of up to 13.8% among a group of obese adults.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.